Wroclaw, Poland, February 22, 2022 - Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, announces over PLN 4 million investment in setting up its own sophisticated proteomics facility in Wrocław, including recruiting experienced proteomics expertise and installing a state-of-the-art mass spectrometry capability.
“We can now support our projects by providing a full proteomic service, which is especially beneficial in the field of targeted protein degradation,” commented Paweł Pasikowski, PhD, Scientific Expert at Captor Therapeutics. "Our main goal is to set up a site for the quantification of our target proteins as well as the identification of off-targe effectss. For this purpose, mass spectrometry coupled with sophisticated separation techniquse is the state-of-the-art tool. Overall, I think the establishment of our own mass spectrometry proteomic facility here in Captor will greatly improve our analytical capabilities and will be a useful addition to our ongoing and future projects."
More information on Captor's Proteomics Lab and its new mass spectrometer can be viewed in a short video presentation here.
About Captor Therapeutics
Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs. TPD is a revolutionary approach to developing new drugs that can address novel molecular targets which are deemed “undruggable” with classical drug development approaches, as well as providing additional treatment options for diseases where existing drugs fail to provide optimal medical benefit. Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.
More information on Captor Therapeutics is available at: http://www.captortherapeutics.com
For further information, please contact:
Polish Media and Investor relations:
Point of View
+48 601 155 582
International Investor Relations:
Guillaume van Renterghem
+41 (0)76 735 01 31